Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.

Article Details

Citation

Copy to clipboard

Martinez-Perez D, Vinal D, Solares I, Espinosa E, Feliu J

Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.

Cancers (Basel). 2021 Nov 27;13(23). pii: cancers13235968. doi: 10.3390/cancers13235968.

PubMed ID

34885078 [ View in PubMed

]

Abstract

Uveal melanoma is a rare neoplasm with poor prognosis in the metastatic setting. Unlike cutaneous melanoma, treatment with kinase inhibitors or immune checkpoint inhibitors is not effective. Glycoprotein 100 (Gp-100) is a protein highly expressed in melanocytes and melanoma that has recently been effectively targeted by tebentafusp, a first-in-class bispecific protein of the immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs) family. Tebentafusp targets tumor cells that express a peptide of Gp-100 presented by HLA*A0201, creating an immune synapse that kills targeted tumor cells. Recently, a randomized phase III trial reported an overall survival benefit for tebentafusp in patients with untreated metastatic uveal melanoma. The aim of this comprehensive review is to summarize evidence of Gp-100 as a therapeutic target in melanoma, and the preclinical and clinical development of tebentafusp as a novel therapeutic strategy for patients with uveal melanoma.

DrugBank Data that Cites this Article

Drugs

Tebentafusp

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tebentafusp	Melanocyte protein PMEL	Protein	Humans	Yes	Binder	Details